image: Fibroblasts positive for meflin in idiopathic pulmonary fibrosis (IPF) view more
Credit: Nakahara Y, Hashimoto N, Sakamoto K, et al. ERJ 2021
Single-cell RNA sequencing has revealed a subset of cells that could provide protection from a rare, but severely debilitating and fatal, lung disease. The findings were published by Nagoya University researchers and colleagues in the European Respiratory Journal. Further research could lead to new therapeutic strategies for the disease, called idiopathic pulmonary fibrosis (IPF).
Approximately 15 in every 100,000 people worldwide develop IPF. Its prognosis and five-year survival rate can be worse than many types of cancer. It involves the development of scar tissue on the lung, impairing gas exchange and making it difficult to breath. The disease currently has no cure and scientists do not know exactly what causes it.
"Our research, led by a collaborative team from Nagoya University in Japan and Yale University in the US, found a special cell population of protective fibroblasts in lungs of people with IPF," says Nagoya University's Naozumi Hashimoto, who specializes in respiratory medicine.
The team examined around 250,000 cells from lung tissue belonging to 29 normal and 32 IPF lungs. The examinations involved sequencing the RNA of each individual cell to find which genes they expressed. The analysis pinpointed one specific subset of fibroblast cells that were significantly more prevalent in IPF lungs than in normal ones. Fibroblasts are the most common type of cell in the supportive tissue in and around organs. This particular subset of fibroblasts produced a protein called meflin.
Interestingly, these meflin-producing fibroblasts were mainly found within acute focal lung lesions on the edges of dense scarring. The surrounding dense scar tissue contained very few of these cells.
Turning off meflin and inducing lung fibrosis in mice triggered cell aging, which led to more extensive pulmonary fibrosis than would have been expected. This process was counteracted in laboratory-studied cells by inserting the gene that codes for meflin.
"We anticipate that our discovery will promote better understanding of the unsolved disease mechanisms of IPF and ultimately lead to the development of novel therapies for lung fibrosis," says Hashimoto.
The team next plans to further investigate how meflin protects lungs from fibrosis and if meflin-positive cells can be used to diagnose and treat IPF.
###
This study, "Fibroblasts positive for meflin have anti-fibrotic property in pulmonary fibrosis," was published in European Respiratory Journal on May 28, 2021, at DOI: 10.1183/13993003.03397-2020.
About Nagoya University, Japan
Nagoya University has a history of about 150 years, with its roots in a temporary medical school and hospital established in 1871, and was formally instituted as the last Imperial University of Japan in 1939. Although modest in size compared to the largest universities in Japan, Nagoya University has been pursuing excellence since its founding. Six of the 18 Japanese Nobel Prize-winners since 2000 did all or part of their Nobel Prize-winning work at Nagoya University: four in Physics - Toshihide Maskawa and Makoto Kobayashi in 2008, and Isamu Akasaki and Hiroshi Amano in 2014; and two in Chemistry - Ryoji Noyori in 2001 and Osamu Shimomura in 2008. In mathematics, Shigefumi Mori did his Fields Medal-winning work at the University. A number of other important discoveries have also been made at the University, including the Okazaki DNA Fragments by Reiji and Tsuneko Okazaki in the 1960s; and depletion forces by Sho Asakura and Fumio Oosawa in 1954.
Website: http://en.nagoya-u.ac.jp/
Journal
European Respiratory Journal